Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GH NYSE:HIMS NASDAQ:NTRA NASDAQ:RDNT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGHGuardant Health$54.90-3.3%$53.81$20.14▼$68.00$7.08B1.462.24 million shs2.78 million shsHIMSHims & Hers Health$55.48+7.2%$50.26$15.73▼$72.98$12.54B2.1423.90 million shs35.41 million shsNTRANatera$168.51-3.0%$155.18$117.27▼$183.00$23.86B1.68978,479 shs853,091 shsRDNTRadNet$74.01+0.4%$63.04$45.00▼$93.65$5.67B1.54621,668 shs678,484 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGHGuardant Health-3.33%-8.70%-6.27%+11.38%+120.75%HIMSHims & Hers Health+7.15%+14.65%+14.77%+0.27%+263.33%NTRANatera-3.05%+0.29%+6.85%+1.92%+36.08%RDNTRadNet+0.38%+3.64%+8.21%+33.57%+18.80%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGHGuardant Health$54.90-3.3%$53.81$20.14▼$68.00$7.08B1.462.24 million shs2.78 million shsHIMSHims & Hers Health$55.48+7.2%$50.26$15.73▼$72.98$12.54B2.1423.90 million shs35.41 million shsNTRANatera$168.51-3.0%$155.18$117.27▼$183.00$23.86B1.68978,479 shs853,091 shsRDNTRadNet$74.01+0.4%$63.04$45.00▼$93.65$5.67B1.54621,668 shs678,484 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGHGuardant Health-3.33%-8.70%-6.27%+11.38%+120.75%HIMSHims & Hers Health+7.15%+14.65%+14.77%+0.27%+263.33%NTRANatera-3.05%+0.29%+6.85%+1.92%+36.08%RDNTRadNet+0.38%+3.64%+8.21%+33.57%+18.80%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGHGuardant Health 3.06Buy$58.246.08% UpsideHIMSHims & Hers Health 1.92Reduce$38.92-29.85% DownsideNTRANatera 3.06Buy$194.0015.13% UpsideRDNTRadNet 3.25Buy$76.803.77% UpsideCurrent Analyst Ratings BreakdownLatest NTRA, HIMS, GH, and RDNT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025HIMSHims & Hers HealthCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$68.009/4/2025GHGuardant HealthBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$65.00 ➝ $70.009/3/2025RDNTRadNetBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$60.00 ➝ $79.009/3/2025RDNTRadNetTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$74.00 ➝ $81.009/2/2025NTRANateraRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOutperform$268.008/19/2025HIMSHims & Hers HealthZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/18/2025HIMSHims & Hers HealthTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$48.00 ➝ $37.008/18/2025RDNTRadNetZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/15/2025NTRANateraStephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$183.008/13/2025RDNTRadNetRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingStrong-Buy$66.00 ➝ $75.008/11/2025RDNTRadNetMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOverweight(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGHGuardant Health$828.85M8.26N/AN/A($1.13) per share-48.58HIMSHims & Hers Health$2.01B6.23$0.38 per share146.98$2.16 per share25.69NTRANatera$1.70B13.63N/AN/A$9.05 per share18.62RDNTRadNet$1.83B3.11$3.50 per share21.17$15.31 per share4.83Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGHGuardant Health-$436.37M-$3.35N/AN/AN/A-49.93%N/A-28.95%11/5/2025 (Estimated)HIMSHims & Hers Health$126.04M$0.8069.35106.693.509.63%26.26%13.06%11/3/2025 (Estimated)NTRANatera-$190.43M-$1.91N/AN/AN/A-12.89%-22.22%-15.03%11/11/2025 (Estimated)RDNTRadNet$2.79M-$0.20N/A139.64N/A-0.78%2.41%0.82%11/10/2025 (Estimated)Latest NTRA, HIMS, GH, and RDNT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/10/2025Q2 2025RDNTRadNet$0.17$0.31+$0.14$0.43$488.06 million$498.23 million8/7/2025Q2 2025NTRANatera-$0.60-$0.74-$0.14-$0.74$476.84 million$546.60 million8/4/2025Q2 2025HIMSHims & Hers Health$0.18$0.17-$0.01$0.17$550.06 million$544.83 million7/30/2025Q2 2025GHGuardant Health-$0.52-$0.44+$0.08-$0.80$211.19 million$232.09 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGHGuardant HealthN/AN/AN/AN/AN/AHIMSHims & Hers HealthN/AN/AN/AN/AN/ANTRANateraN/AN/AN/AN/AN/ARDNTRadNetN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGHGuardant HealthN/A3.713.35HIMSHims & Hers Health1.724.984.46NTRANateraN/A3.723.58RDNTRadNet0.912.002.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGHGuardant Health92.60%HIMSHims & Hers Health63.52%NTRANatera99.90%RDNTRadNet77.90%Insider OwnershipCompanyInsider OwnershipGHGuardant Health6.10%HIMSHims & Hers Health13.71%NTRANatera5.63%RDNTRadNet5.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGHGuardant Health2,021124.71 million117.10 millionNot OptionableHIMSHims & Hers Health1,637226.02 million195.03 millionOptionableNTRANatera4,434137.25 million129.52 millionOptionableRDNTRadNet11,02176.92 million72.61 millionOptionableNTRA, HIMS, GH, and RDNT HeadlinesRecent News About These CompaniesNorman Hames Sells 10,000 Shares of RadNet (NASDAQ:RDNT) StockSeptember 13 at 6:38 AM | insidertrades.comRadNet (NASDAQ:RDNT) CEO Cornelis Wesdorp Sells 500 SharesSeptember 12 at 5:52 PM | marketbeat.comInsider Selling: RadNet (NASDAQ:RDNT) CEO Sells 500 Shares of StockSeptember 11 at 8:38 AM | insidertrades.comFred Alger Management LLC Raises Holdings in RadNet, Inc. $RDNTSeptember 11 at 4:56 AM | marketbeat.comAxiom Investors LLC DE Trims Stake in RadNet, Inc. $RDNTSeptember 10 at 8:47 AM | marketbeat.comRadNet, Inc. (RDNT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 10 at 4:02 AM | seekingalpha.comRoyal Bank of Canada Increases Stake in RadNet, Inc. $RDNTSeptember 10 at 3:35 AM | marketbeat.comAdage Capital Partners GP L.L.C. Sells 27,655 Shares of RadNet, Inc. $RDNTSeptember 9, 2025 | marketbeat.comRadNet, Inc. to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9th, 2025September 8, 2025 | globenewswire.comPunch & Associates Investment Management Inc. Raises Holdings in RadNet, Inc. $RDNTSeptember 8, 2025 | marketbeat.comAlyeska Investment Group L.P. Acquires 712,270 Shares of RadNet, Inc. $RDNTSeptember 6, 2025 | marketbeat.comRadNet (NASDAQ:RDNT) Price Target Raised to $81.00September 6, 2025 | americanbankingnews.comBarclays Raises RadNet (NASDAQ:RDNT) Price Target to $79.00September 5, 2025 | marketbeat.comTruist Financial Forecasts Strong Price Appreciation for RadNet (NASDAQ:RDNT) StockSeptember 5, 2025 | marketbeat.com1 High-Flying Stock for Long-Term Investors and 2 We AvoidSeptember 4, 2025 | finance.yahoo.comRadNet price target raised to $81 from $74 at TruistSeptember 3, 2025 | msn.comRadNet price target raised to $79 from $60 at BarclaysSeptember 3, 2025 | msn.comRadNet, Inc. $RDNT Shares Acquired by Beck Mack & Oliver LLCSeptember 2, 2025 | marketbeat.comKingdon Capital Management L.L.C. Invests $3.83 Million in RadNet, Inc. $RDNTSeptember 1, 2025 | marketbeat.comAmeriprise Financial Inc. Increases Stake in RadNet, Inc. $RDNTSeptember 1, 2025 | marketbeat.comNorthern Trust Corp Sells 25,927 Shares of RadNet, Inc. $RDNTSeptember 1, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines5 High Short-Interest Stocks to Buy Before NovemberBy Thomas Hughes | August 20, 2025Can AI Defense Contracts Push Palantir Shares Higher?By Chris Markoch | August 19, 2025Amazon Stock Sets Up for Breakout After Bullish CrossoverBy Sam Quirke | August 21, 2025Take Profits Now: 3 Overbought Stocks Primed for a PullbackBy Dan Schmidt | August 25, 2025NVIDIA Stock Could Pull Back in September, But Don’t Bet on ItBy Thomas Hughes | August 28, 2025NTRA, HIMS, GH, and RDNT Company DescriptionsGuardant Health NASDAQ:GH$54.90 -1.89 (-3.33%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$54.92 +0.02 (+0.05%) As of 09/12/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.Hims & Hers Health NYSE:HIMS$55.48 +3.72 (+7.19%) Closing price 09/12/2025 03:59 PM EasternExtended Trading$54.98 -0.50 (-0.91%) As of 09/12/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.Natera NASDAQ:NTRA$168.51 -5.30 (-3.05%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$171.25 +2.74 (+1.63%) As of 09/12/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.RadNet NASDAQ:RDNT$74.01 +0.28 (+0.38%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$74.03 +0.02 (+0.02%) As of 09/12/2025 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
